{"entity":{"id":"nct05205850","kind":"trial","name":"A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of RC118-ADC in advanced solid tumours, run by RemeGen Co., Ltd., now recruiting.","summary":"A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors is a phase 1/2 interventional study registered as NCT05205850 by RemeGen Co., Ltd., with 135 participants planned, started 2022-03-03 and due to reach its primary completion in 2025-09-30. Interventions recorded: RC118-ADC.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05205850","url":"https://clinicaltrials.gov/study/NCT05205850"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["rc118-adc"],"companies":["remegen"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05205850","phase":"1/2","setting":"An Open, Multi-center Phase I/IIa Clinical Study of RC118 for Injection in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors with Positive Expression of Claudin 18.2","sponsor":"RemeGen Co., Ltd.","enrolled":135,"outcomes":[]},"route":"/trials/nct05205850/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"rc118-adc","kind":"drug","name":"RC118-ADC","route":"/drugs/rc118-adc/"}],"company":[{"id":"remegen","kind":"company","name":"RemeGen","route":"/companies/remegen/"}]}}